Disparities in osteoporosis treatments

Osteoporosis International

Volumn 27, Issue 2, 2016, Pages 509-519

  Liu, Z ^a   Weaver, J ^b   de Papp, A ^b   Li, Z ^c   Martin, J ^d   Allen, K ^d   Hui, S ^d   Imel, E A ^e  

^a INDIANA UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d REGENSTRIEF INSTITUTE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Denosumab; Fracture; Healthcare disparities; Osteoporosis; Osteoporosis treatment; Raloxifene; Teriparatide

Indexed keywords

ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARATHYROID HORMONE[1-34]; PROTON PUMP INHIBITOR; RALOXIFENE; THIAZIDE DIURETIC AGENT; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; COHORT ANALYSIS; COMORBIDITY; ELECTRONIC MEDICAL RECORD; FEMALE; FRAGILITY FRACTURE; HEALTH CARE DISPARITY; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; OBSERVATIONAL STUDY; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; VITAMIN D DEFICIENCY; DRUG EFFECTS; DRUG UTILIZATION; INDIANA; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; DRUG UTILIZATION; FEMALE; HEALTHCARE DISPARITIES; HUMANS; INDIANA; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES;

EID: 84957437107     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3249-0     Document Type: Article

References (36)

1. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res:Off J Am Soc Bone Miner Res 29:2520–2526
2. Stevens JA, Rudd RA (2013) The impact of decreasing U.S. hip fracture rates on future hip fracture estimates. Osteoporos Int: J Estab Result Coop Between European Found Osteoporos Natl Osteoporos Found USA 24:2725–2728
3. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res: Official J Am Soc Bone Miner Res 22:465–475
4. Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res: Off J Am Soc Bone Miner Res 29:1929–1937
5. Colon-Emeric C, Lyles KW, Levine DA et al (2007) Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int: J Estab Result Coop Between European Found Osteoporos Natl Osteoporos Found USA 18:553–559
6. Parikh S, Mogun H, Avorn J, Solomon DH (2008) Osteoporosis medication use in nursing home patients with fractures in 1 US state. Arch Intern Med 168:1111–1115
7. Bessette L, Jean S, Davison KS, Roy S, Ste-Marie LG, Brown JP (2009) Factors influencing the treatment of osteoporosis following fragility fracture. Osteoporos Int: J Estab Result Coop Between European Found Osteoporos Natl Osteoporos Found USA 20:1911–1919
8. McGowan BM, Bennett K, Marry J, Walsh JB, Casey MC (2011) Primary-care prescribing of anti-osteoporotic-type medications following hospitalisation for fractures. Eur J Clin Pharmacol 67:301–308
9. Greenspan SL, Wyman A, Hooven FH et al (2012) Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc 60:455–461
10. Beaton DE, Dyer S, Jiang D, Sujic R, Slater M, Sale JE, Bogoch ER, Osteoporosis Fracture Clinic Screening Program Evaluation T (2014) Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy’s fracture clinic screening program. Osteoporos Int: J Estab Result Coop Between European Found Osteoporos Natl Osteoporos Found USA 25:289–296
11. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35:293–305
12. Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58:650–657
13. Kung AW, Fan T, Xu L et al (2013) Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens health 13:7
14. Jean S, Candas B, Belzile E, Morin S, Bessette L, Dodin S, Brown JP (2012) Algorithms can be used to identify fragility fracture cases in physician-claims databases. Osteoporos Int 23:483–501
15. Lix LM, Azimaee M, Osman BA, Caetano P, Morin S, Metge C, Goltzman D, Kreiger N, Prior J, Leslie WD (2012) Osteoporosis-related fracture case definitions for population-based administrative data. Bmc Public Health 12:
16. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton E, Saag KG (2009) Identification and validation of vertebral compression fractures using administrative claims data. Med Care 47:69–72
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
18. MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213
19. Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526
20. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381
21. Diez-Perez A, Hooven FH, Adachi JD et al (2011) Regional differences in treatment for osteoporosis. The global longitudinal study of osteoporosis in women (GLOW). Bone 49:493–498
22. Antonelli M, Einstadter D, Magrey M (2014) Screening and treatment of osteoporosis after hip fracture: comparison of sex and race. J Clin Densitom 17:479–483
23. Shibli-Rahhal A, Vaughan-Sarrazin MS, Richardson K, Cram P (2011) Testing and treatment for osteoporosis following hip fracture in an integrated US healthcare delivery system. Osteoporos Int 22:2973–2980
24. Harper CM, Fitzpatrick SK, Zurakowski D, Rozental TD (2014) Distal radial fractures in older men. A missed opportunity? J Bone Joint Surg Am 96:1820–1827
25. Cunningham TD, Di Pace BS, Ullal J (2014) Osteoporosis treatment disparities: a 6-year aggregate analysis from national survey data. Osteoporos Int 25:2199–2208
26. Wright NC, Saag KG, Curtis JR, Smith WK, Kilgore ML, Morrisey MA, Yun H, Zhang J, Delzell ES (2012) Recent trends in hip fracture rates by race/ethnicity among older US adults. J Bone Min Res: Off J Am Soc Bone Miner Res 27:2325–2332
27. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care pharm 17:25–39
28. Armstrong ME, Cairns BJ, Banks E, Green J, Reeves GK, Beral V, Million Women Study C (2012) Different effects of age, adiposity and physical activity on the risk of ankle, wrist and hip fractures in postmenopausal women. Bone 50:1394–1400
29. Moura C, Bernatsky S, Abrahamowicz M et al (2014) Antidepressant use and 10-year incident fracture risk: the population-based Canadian multicentre osteoporosis study (CaMoS). Osteoporos Int: J Established Result Coop Between European Found Osteoporos Natl Osteoporos Found USA 25:1473–1481
30. Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884
31. Osteoporosis testing and management in older women. National Committee for Quality Assurance (NCQA). http://www.ncqa.org/ReportCards/HealthPlans/StateofHealthCareQuality/2014TableofContents/Osteoporosis.aspx
32. Wysowski DK, Greene P (2013) Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012. Bone 57:423–428
33. Reid IR (Accepted) Efficacy, effectiveness and side effects of medications used to prevent fractures. Journal of Internal Medicine
34. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg: Off J Am Assoc Oral Maxillofac Surgeons 61:1115–1117
35. Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Min Res: Off J Am Soc Bone Min Res 25:2267–2294
36. Neuner JM, Schapira MM (2014) Patient perceptions of osteoporosis treatment thresholds. J Rheumatol 41:516–522